Soluble factors secreted by glioblastoma cell lines facilitate recruitment, survival, and expansion of regulatory T cells: implications for immunotherapy.
about
Immune Evasion Strategies of GlioblastomaImmunosuppressive Mechanisms of Malignant Gliomas: Parallels at Non-CNS SitesImmunotherapy advances for glioblastomaAn update on vaccine therapy and other immunotherapeutic approaches for glioblastomaCombining Radiation Therapy with Immune Checkpoint Blockade for Central Nervous System MalignanciesImmunocompetent murine models for the study of glioblastoma immunotherapyStable luciferase expression does not alter immunologic or in vivo growth properties of GL261 murine glioma cellsPharmacokinetic, pharmacodynamic and biomarker evaluation of transforming growth factor-β receptor I kinase inhibitor, galunisertib, in phase 1 study in patients with advanced cancer.Regulatory T cells are not a strong predictor of survival for patients with glioblastoma.Immunosuppressive mechanisms in glioblastoma.Immunotherapy for neuro-oncology: the critical rationale for combinatorial therapy.Differential correlation analysis of glioblastoma reveals immune ceRNA interactions predictive of patient survivalIDO expression in brain tumors increases the recruitment of regulatory T cells and negatively impacts survivalMelanoma growth effects on molecular clearance from tumors and biodistribution into systemic tissues versus draining lymph nodes.Irradiation of necrotic cancer cells, employed for pulsing dendritic cells (DCs), potentiates DC vaccine-induced antitumor immunity against high-grade glioma.Multifaceted oncolytic virus therapy for glioblastoma in an immunocompetent cancer stem cell model.Gliomas promote immunosuppression through induction of B7-H1 expression in tumor-associated macrophagesImmune-checkpoint blockade and active immunotherapy for glioma.Heme oxygenase-1 protects regulatory T cells from hypoxia-induced cellular stress in an experimental mouse brain tumor model.Targeting Tregs in Malignant Brain Cancer: Overcoming IDO.Microenvironmental clues for glioma immunotherapy.Combining immunotherapy with radiation for the treatment of glioblastoma.The Dynamics of Interactions Among Immune and Glioblastoma Cells.An Update on the Role of Immunotherapy and Vaccine Strategies for Primary Brain Tumors.Relationship between expression of PD-L1 and tumor angiogenesis, proliferation, and invasion in glioma.Developing immunotherapeutic strategies to target brain tumors.Enhanced immunosuppression by therapy-exposed glioblastoma multiforme tumor cells.Circulating T regulatory cells migration and phenotype in glioblastoma patients: an in vitro study.Engineering challenges for brain tumor immunotherapy.CCL2 Produced by the Glioma Microenvironment Is Essential for the Recruitment of Regulatory T Cells and Myeloid-Derived Suppressor Cells.Depletion of regulatory T cells in a mouse experimental glioma model through anti-CD25 treatment results in the infiltration of non-immunosuppressive myeloid cells in the brain.Intratumoral oncolytic adenoviral treatment modulates the glioma microenvironment and facilitates systemic tumor-antigen-specific T cell therapy.Serum exosomes and cytokines promote a T-helper cell type 2 environment in the peripheral blood of glioblastoma patientsInterleukin 21 inhibits cancer-mediated FOXP3 induction in naïve human CD4 T cellsMore on the immune privilege of glioblastoma.Treg infiltration in glioma: a hurdle for antiglioma immunotherapy.Assessment and prognostic significance of the epidermal growth factor receptor vIII mutation in glioblastoma patients treated with concurrent and adjuvant temozolomide radiochemotherapy.T-Cell Dysfunction in Glioblastoma: Applying a New Framework.Glioblastoma multiforme-derived extracellular vesicles drive normal astrocytes towards a tumour-enhancing phenotype.Immune Microenvironment in Glioblastoma Subtypes.
P2860
Q26765855-367AEA79-5C52-4236-977E-B67C31106718Q26798402-74283FD2-04C0-44DA-8362-6258FC621969Q26866513-BCBE6EA5-713F-4C4E-BA0A-8F1B535F5872Q27024830-F5A34D99-C13D-40A0-9D09-E4D2A6C033FEQ28072007-77AC2928-20D9-415D-8831-2472773F1D05Q33574853-59088505-5B84-4B43-B578-A4FD7E868BF3Q34645287-9E956C08-D865-4BA8-B9D3-A759CA3051C3Q35289038-F3610FB6-87F8-4935-A4E5-2F0753466C28Q35789008-C1746186-B1EA-4BEE-A126-68AA9766ECBFQ36224048-8C6A69A0-75C6-4690-BBB0-C0594A350FE8Q36224057-7495749E-FA8F-47FE-BD0A-C1FE50BCC0A1Q36292015-B7A64090-0EC2-47B7-877D-2A3A5440C23EQ36405905-E58516FF-2D12-4518-8957-BA3EB8AC8B19Q36494851-EBC5A3C8-C72D-4D8A-9C65-FA4BAEFA27BDQ36710917-59754A2B-0CBA-4F1C-861D-7C881DF4501CQ37031739-7372962D-5000-45CE-9AC2-FAFFEDD0188DQ37092938-6371CE34-93E4-47B0-932B-932F70095702Q37420586-05AB44E7-4C36-43BB-99FA-6A2D5EA6B075Q37598477-AC5E893D-571B-493A-8AE2-54EAA48C678AQ38110540-1E78D813-F0D5-4365-B761-440B5BA54A5BQ38194054-5A7EB648-707A-4253-A1D8-BEF9E21EA193Q38422623-41D216B7-9CC3-4682-A3EB-DD4FDC13DDADQ38557236-C1170F1D-F55D-4D6F-8032-B3D27B24AB34Q38603909-09A49E02-E930-45DD-BEF4-43B0ED27679DQ38737954-D4EB1C91-D0F1-43D5-8E9D-8987E95168A3Q38851464-85D0B0A0-5F0F-408A-B00B-10EDDF2C9EF2Q38943301-64CE4F31-CC1C-4C68-93CE-F170DBEB60B2Q39100186-54224C39-61CE-4032-BAE2-205A360BB63EQ39381281-D5615C3F-F0E4-4C09-9642-F5668BA3F51DQ40619963-8273F4AB-A9F6-4D49-8DFF-D61B5B0C84FAQ40752470-18EA9FCF-497D-4382-8768-9DF1228FB413Q40982444-EC9047F6-B3BE-483C-B3EF-7AB38E8B88CEQ42234796-D4E64464-D2D1-48A9-8772-E97F5121731AQ42290425-90BA3B3A-C224-42F8-97E4-C77D77ECF2FBQ43054945-0F35D8AE-5A8A-4FD2-9F56-74637C99C43DQ44315396-5978E711-3C61-4D27-B684-5CCB3E548031Q45036488-B7705E45-D2AC-46BE-BD3A-EF4BEDE2E226Q52625023-ADA8176F-692C-4C2C-B5DE-A16475A25FB7Q52776751-861247C3-E44B-481E-9320-E03A88051FBAQ55261256-CFEF00F1-F2E5-40B2-B29E-9182A8FEA61F
P2860
Soluble factors secreted by glioblastoma cell lines facilitate recruitment, survival, and expansion of regulatory T cells: implications for immunotherapy.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Soluble factors secreted by gl ...... mplications for immunotherapy.
@en
Soluble factors secreted by gl ...... mplications for immunotherapy.
@nl
type
label
Soluble factors secreted by gl ...... mplications for immunotherapy.
@en
Soluble factors secreted by gl ...... mplications for immunotherapy.
@nl
prefLabel
Soluble factors secreted by gl ...... mplications for immunotherapy.
@en
Soluble factors secreted by gl ...... mplications for immunotherapy.
@nl
P2093
P2860
P356
P1433
P1476
Soluble factors secreted by gl ...... mplications for immunotherapy.
@en
P2093
Andrew T Parsa
Brian J Ahn
Courtney A Crane
Seunggu J Han
P2860
P304
P356
10.1093/NEUONC/NOS014
P577
2012-03-09T00:00:00Z